NEW YORK (GenomeWeb News) – Indian contract research organization GVK Biosciences today announced the licensing of its clinical biomarker database to the National Institutes of Health's National Cancer Institute.
The database called GOBIOM is being licensed to NCI's Division of Cancer Prevention. Financial and other terms of the deal were not disclosed.
GOBIOM comprises all clinically evaluated exploratory and preclinical biomarkers that are associated with therapeutic areas reported in clinical trials, as well as clinical and preclinical studies that have been conducted worldwide, GVK said. It contains data for 15,500 biochemical, genomic, imaging, metabolite, cellular and physiological biomarkers with multiple data points covering experimental, analytical, clinical, preclinical, and statistical data with their qualifications under different medical interventions.
GOBIOM covers more than 100 different ethnicities, GVK Biosciences added, providing information on approved assay methodologies and companion diagnostics, and it has more than 6,000 clinically evaluated cancer biomarkers.
GVK is based in Hyderabad, India and provides stand-alone and integrated services covering R&D processes.